EGFR testing (A molecular test) in advanced Lung cancer in patients treated with radiation therapy.
Not Applicable
- Conditions
- Health Condition 1: null- Advanced Lung cancer patients
- Registration Number
- CTRI/2017/05/008651
- Lead Sponsor
- ot Applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
All patients with locally advanced Non-small cell lung cancer treated with radical intent with radiotherapy or chemo-radiotherapy. All patients should have biopsy to do EGFR mutation analysis
Exclusion Criteria
Patients without an available biopsy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To determine the rate of EGFR mutation in locally advanced NSCLC patients treated with radical thoracic radiation.Timepoint: 2 months after completion of Radiotherapy.
- Secondary Outcome Measures
Name Time Method 1.To evaluate the effect of EGFR mutation on response rate in locally advanced NSCLC patients treated with radical thoracic radiation. <br/ ><br>2.To evaluate the effect of EGFR mutation on progression free survival in locally advanced NSCLC patients treated with radical thoracic radiation <br/ ><br>3.To evaluate the effect of EGFR mutation on overall survival in locally advanced NSCLC patients treated with radical thoracic radiation <br/ ><br>Timepoint: 1. On Baseline Biopsy <br/ ><br>2. & 3. At Progression & at Death